Coherus Biosciences
NASDAQ: CHRSUnicorn · $1.1BRedwood City, US · Founded 2010 · Delaware corporation · 208 employees on LinkedIn · 4 known investors
Find your way into Coherus Biosciences
132 people in our graph share verified history with the Coherus Biosciences team — schools, employers, funds. One of them is your warm intro.
Desmond Padhiunlockedknows Denny Lanfear · together at Amgen (overlapped)
×11knows the team · via Amgen
Coherus Oncology develops and commercializes immuno-oncology therapies, including the approved LOQTORZI, to treat patients with cancer. The company focuses on expanding its pipeline of clinical-stage candidates targeting the tumor microenvironment.
Founders & leadership
Coherus Biosciences was founded in 2010 by Dennis M. Lanfear and Denny Lanfear.
DM
Dennis M. LanfearCo-founder
DL
Denny LanfearinChairman, Founder, and CEO of Coherus OncologyDenny Lanfear is the Founder, Chairman, and CEO of Coherus Oncology, an immuno-oncology company he started in 2010 and took public in 2014. With experience spanning metabolic disease, ophthalmology, and immuno-oncology, he has worked in corporate finance, strategy, licensing, and M&A, and founded the pharmaceutical manufacturing advocacy nonprofit "Securing America's Medicine and Supply."
AC
Alan C. HermaninChief Scientific Officer2011–2018
JV
Jean-Frederic Viret, Ph.D.Executive
PK
Peter K. Watler, Ph.D.Executive
BK
Barbara K Finck, M.D.Named on SEC filing
Board
AJ
Ali J. SatvatBoard director
JI
James I. Healy, M.D., Ph.D.Board director
GK
Graham K. Crooke, M.D.Board director
MW
Mats WahlstromBoard director
CR
Christos RichardsBoard director
MT
Mary T. SzelaBoard director
Investors · 4
Reported raises · per SEC filings
Form D private placements$85.3M disclosed across 4 rounds · 2011–2017
▶$6.8MraisedDec 2017 · 1 investors · Other Health CareRule 506(b)
▶$6.8MraisedDec 2017 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- V. Bryan LawlisDirector
- Mats WahlstromDirector
- Dennis M. LanfearExecutive Officer, Director
- Barbara K. Finck, M.D.Executive Officer
- Peter K. Watler, Ph.D.Executive Officer
- August J. Troendle, M.D.Director
- Alan C. HermanExecutive Officer
- Jean Frederic Viret, Ph.D.Executive Officer
- James I. Healy, M.D., Ph.D.Director
- Christos RichardsDirector
- Mary T. SzelaDirector
- Ali J. SatvatDirector
- Offering amount
- $6.8M
- Amount sold
- $6.8M
- First sale
- Dec 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10MraisedSep 2015 · 1 investors · Other Health CareRule 506(b)
▶$10MraisedSep 2015 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Barbara K Finck, M.D.Executive Officer
- Ali J. SatvatDirector
- Mats WahlstromDirector
- Alan C. HermanExecutive Officer
- Dennis M. LanfearExecutive Officer, Director
- Jean-Frederic Viret, Ph.D.Executive Officer
- Christos RichardsDirector
- Mary T. SzelaDirector
- August J. Troendle, M.D.Director
- V. Bryan Lawlis, Ph.D.Director
- Peter K. Watler, Ph.D.Executive Officer
- James I. Healy, M.D., Ph.D.Director
- Offering amount
- $10M
- Amount sold
- $10M
- First sale
- Sep 2015
- Incorporated
- Corporation, Delaware, 2010
- Federal exemptions
- 06b
▶$55.6MraisedJun 2014 · 35 investors · Other Health CareRule 506(b)
▶$55.6MraisedJun 2014 · 35 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- J. Michael Lazarus, M.D.Director
- Alan C. HermanExecutive Officer
- Barbara K. Finck, M.D.Executive Officer
- George G. MontgomeryExecutive Officer
- Christos RichardsDirector
- Dennis M. LanfearExecutive Officer, Director
- Mats WahlstromDirector
- Ali J. SatvatDirector
- James I. Healy, M.D., Ph.D.Director
- August J. Troendle, M.D.Director
- S. Edward TorresDirector
- Offering amount
- $65.6M
- Amount sold
- $55.6M
- First sale
- May 2014
- Incorporated
- Corporation, Delaware, 2010
- Federal exemptions
- 06b
▶$12.9MraisedJan 2012 · 15 investors · Other Health CareRule 506(b)
▶$12.9MraisedJan 2012 · 15 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Stuart E. Builder, Ph.D.Director
- Christos RichardsDirector
- John Michael Lazarus, M.D.Director
- Dennis M. LanfearExecutive Officer, Director
- August J. Troendle, M.D.Director
- Mats WahlstromDirector
- Graham K. Crooke, M.D.Director
- Offering amount
- $14.3M
- Amount sold
- $12.9M
- Minimum investment
- $1
- First sale
- Jul 2011
- Incorporated
- Corporation, Delaware, 2010
- Federal exemptions
- 06
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$1.1Bvaluation at IPOApr 2015 · $29.00/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Competitors · 4
by search overlap
Agenus53 shared keywordsAgenus is a biotechnology company developing cancer immunotherapies, including its lead investigational combination of botensilimab (an anti-CTLA-4 antibody) and balstilimab (a PD-1 inhibitor), known as BOT+BAL. It provides access to these investigational medicines for cancer patients through pathways such as clinical trials, Named Patient Programs, and compassionate-use programs across multiple countries.
Amicus Therapeutics44 shared keywordsAmicus is a rare disease biotechnology company developing medicines for people with genetically defined conditions. It operates as a wholly owned subsidiary of BioMarin Pharmaceutical Inc.
Seeking Alpha41 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Robinhood40 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Companies competing with Coherus Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.
Acquisitions · 1
Early investors' stakes continue via these dealsSurface Oncology
Surface Oncology was a Cambridge, MA clinical-stage immuno-oncology biotech developing antibody therapies targeting the tumor microenvironment, including candidates against IL-27 and CCR8.
In the news
Frequently asked questions
- What does Coherus Biosciences do?
- Coherus Oncology develops and commercializes immuno-oncology therapies, including the approved LOQTORZI, to treat patients with cancer. The company focuses on expanding its pipeline of clinical-stage candidates targeting the tumor microenvironment.
- Who founded Coherus Biosciences?
- Coherus Biosciences was founded by Dennis M. Lanfear, Denny Lanfear in 2010.
- Who are Coherus Biosciences's investors?
- Coherus Biosciences's investors include F-Prime Capital, HEALTHCARE ROYALTY PARTNERS, Sofinnova Ventures, Venrock.
- How much funding has Coherus Biosciences raised?
- Coherus Biosciences has disclosed $85.3M raised across 4 rounds.
- Where is Coherus Biosciences headquartered?
- Coherus Biosciences is headquartered in Redwood City, US.